Effect of Atorvastatin on Haemostasis, Fibrinolysis and Inflammation in Normocholesterolaemic Patients with Coronary Artery Disease: a Post Hoc Analysis of Data from a Prospective, Randomized, Double-blind Study

Overview

Journal Clin Drug Investig

Date 2010 May 6

PMID 20441243

Citations 5

Authors

Thomas Walter

Sebastian Szabo

Tim Suselbeck

Martin Borggrefe

Siegfried Lang

Stefanie Swoboda

Hans Martin Hoffmeister

Carl-Erik Dempfle

Affiliations

Soon will be listed here.

Abstract

Background: Treatment with HMG-CoA reductase inhibitors (statins) reduces the morbidity and mortality of coronary artery disease (CAD). In addition to their lipid-lowering actions, pleiotropic effects of statins have been demonstrated.

Objective: The aim of the present study was to assess if atorvastatin therapy has an impact on haemostasis, fibrinolysis and inflammation in normocholesterolaemic patients with CAD.

Methods: Fifty-four patients with CAD who had received atorvastatin treatment for at least 8 weeks (mean dosage 30 mg/day) and 54 patients with CAD who had not received atorvastatin therapy were selected from a larger prospective, randomized, double-blind study for inclusion in this post hoc analysis. Patients were matched by their total cholesterol levels. All patients were normocholesterolaemic.

Results: In the atorvastatin-treated patients significantly lower plasma levels of thrombin-antithrombin complexes (p < 0.05), plasminogen activator inhibitor-1 activity (PAI-1) [p < 0.05], soluble vascular cell adhesion molecule-1 (p < 0.05), soluble platelet selectin (p < 0.05) and high-sensitivity C-reactive protein (p < 0.05) were measured compared with patients not on atorvastatin therapy. Additionally, a strong trend towards lower soluble intercellular adhesion molecule-1 plasma levels was detected in patients treated with atorvastatin. No differences were found in tissue-type plasminogen activator antigen, plasmin-plasmin inhibitor complexes, fibrinogen, D-dimer and activated factor XII values.

Conclusion: Atorvastatin appears to have an effect on coagulation activation, fibrinolysis and inflammation in patients with CAD. Reduction in PAI-1 and reduced thrombin formation may have an impact on cardiovascular morbidity and mortality in patients with CAD.

Citing Articles

Diabetes Mellitus/Poststroke Hyperglycemia: a Detrimental Factor for tPA Thrombolytic Stroke Therapy.

Jiang Y, Liu N, Han J, Li Y, Spencer P, Vodovoz S Transl Stroke Res. 2020; 12(3):416-427.

PMID: 33140258 DOI: 10.1007/s12975-020-00872-3.

Clinical effects of antiplatelet drugs and statins on D-dimer levels.

Schol-Gelok S, van der Hulle T, Biedermann J, van Gelder T, Klok F, van der Pol L Eur J Clin Invest. 2018; 48(7):e12944.

PMID: 29682728 PMC: 6055760. DOI: 10.1111/eci.12944.

Anti-inflammatory and anti-thrombogenic effects of atorvastatin in acute ischemic stroke.

Min L, Shao S, Wu X, Cong L, Liu P, Zhao H Neural Regen Res. 2014; 8(23):2144-54.

PMID: 25206523 PMC: 4146119. DOI: 10.3969/j.issn.1673-5374.2013.23.004.

Statin therapy and levels of hemostatic factors in a healthy population: the Multi-Ethnic Study of Atherosclerosis.

Adams N, Lutsey P, Folsom A, Herrington D, Sibley C, Zakai N J Thromb Haemost. 2013; 11(6):1078-84.

PMID: 23565981 PMC: 3702638. DOI: 10.1111/jth.12223.

Plasminogen activator inhibitor-1 and thrombotic cerebrovascular diseases.

Tjarnlund-Wolf A, Brogren H, Lo E, Wang X Stroke. 2012; 43(10):2833-9.

PMID: 22879095 PMC: 3712849. DOI: 10.1161/STROKEAHA.111.622217.

References

Ozaki K, Kubo T, Imaki R, Shinagawa H, Fukaya H, Ohtaki K . The anti-atherosclerotic effects of lipid lowering with atorvastatin in patients with hypercholesterolemia. J Atheroscler Thromb. 2006; 13(4):216-9. DOI: 10.5551/jat.13.216. View

Bruni F, Pasqui A, Pastorelli M, Bova G, Di Renzo M, Cercigani M . Effect of atorvastatin on different fibrinolyis mechanisms in hypercholesterolemic subjects. Int J Cardiol. 2004; 95(2-3):269-74. DOI: 10.1016/j.ijcard.2003.08.003. View

Trifiletti A, Lasco A, Scamardi R, Pizzoleo M, Gaudio A, La Rocca R . Long-term hemostatic effects of cholesterol-lowering therapy with atorvastatin. Pathophysiol Haemost Thromb. 2003; 33(2):84-7. DOI: 10.1159/000073851. View

Puccetti L, Pasqui A, Pastorelli M, Bova G, Cercignani M, Palazzuoli A . Time-dependent effect of statins on platelet function in hypercholesterolaemia. Eur J Clin Invest. 2003; 32(12):901-8. DOI: 10.1046/j.1365-2362.2002.01086.x. View

Wiesbauer F, Kaun C, Zorn G, Maurer G, Huber K, Wojta J . HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins. Br J Pharmacol. 2002; 135(1):284-92. PMC: 1573117. DOI: 10.1038/sj.bjp.0704454. View

Son J, Kon Koh K, Ahn J, Jin D, Park G, Kim D . Effects of statin on plaque stability and thrombogenicity in hypercholesterolemic patients with coronary artery disease. Int J Cardiol. 2003; 88(1):77-82. DOI: 10.1016/s0167-5273(02)00368-6. View

Blanco-Colio L, Martin-Ventura J, de Teresa E, Farsang C, Gaw A, Gensini G . Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified.... Am Heart J. 2007; 153(5):881-8. DOI: 10.1016/j.ahj.2007.02.029. View

Alber H, Frick M, Sussenbacher A, Dorler J, Dichtl W, Stocker E . Effect of atorvastatin on peripheral endothelial function and systemic inflammatory markers in patients with stable coronary artery disease. Wien Med Wochenschr. 2007; 157(3-4):73-8. DOI: 10.1007/s10354-007-0377-y. View

Puccetti L, Sawamura T, Pasqui A, Pastorelli M, Auteri A, Bruni F . Atorvastatin reduces platelet-oxidized-LDL receptor expression in hypercholesterolaemic patients. Eur J Clin Invest. 2005; 35(1):47-51. DOI: 10.1111/j.1365-2362.2005.01446.x. View

10.

. ECAT angina pectoris study: baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J. 1993; 14(1):8-17. DOI: 10.1093/eurheartj/14.1.8. View

11.

Lopez S, Peiretti F, Bonardo B, Juhan-Vague I, Nalbone G . Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells. Atherosclerosis. 2000; 152(2):359-66. DOI: 10.1016/s0021-9150(00)00454-8. View

12.

Tekin A, Tekin G, Guzelsoy D, Kaya A, Gurel C, Yigit Z . Effects of atorvastatin (10 mg) on hemostatic and inflammatory parameters in hyperlipidemic patients with angiographically proven coronary artery disease. Am J Cardiol. 2004; 94(2):206-9. DOI: 10.1016/j.amjcard.2004.03.065. View

13.

Seljeflot I, Tonstad S, Hjermann I, Arnesen H . Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease. Thromb Res. 2002; 105(4):285-90. DOI: 10.1016/s0049-3848(02)00034-8. View

14.

Bruni F, Pasqui A, Pastorelli M, Bova G, Cercignani M, Palazzuoli A . Different effect of statins on platelet oxidized-LDL receptor (CD36 and LOX-1) expression in hypercholesterolemic subjects. Clin Appl Thromb Hemost. 2005; 11(4):417-28. DOI: 10.1177/107602960501100408. View

15.

Garcia Frade L, ALVAREZ J, Rayo I, Torrado M, Lasuncion M, Garcia Avello A . Fibrinolytic parameters and lipoprotein (a) levels in plasma of patients with coronary artery disease. Thromb Res. 1991; 63(4):407-18. DOI: 10.1016/0049-3848(91)90227-n. View

16.

Hoffmeister H, Jur M, Wendel H, Heller W, Seipel L . Alterations of coagulation and fibrinolytic and kallikrein-kinin systems in the acute and postacute phases in patients with unstable angina pectoris. Circulation. 1995; 91(10):2520-7. DOI: 10.1161/01.cir.91.10.2520. View

17.

Ray K, Cannon C, Cairns R, Morrow D, Rifai N, Kirtane A . Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2005; 46(8):1417-24. DOI: 10.1016/j.jacc.2005.08.024. View

18.

Hackman A, Abe Y, INSULL Jr W, Pownall H, Smith L, Dunn K . Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation. 1996; 93(7):1334-8. DOI: 10.1161/01.cir.93.7.1334. View

19.

Kushiya F, Wada H, Ooi K, Sakurai Y, Sakaguchi A, Noda M . Effects of atorvastatin on serum lipids, lipoproteins, and hemostasis. Am J Hematol. 2004; 78(1):1-6. DOI: 10.1002/ajh.20191. View

20.

Brown N, Agirbasli M, Williams G, Litchfield W, Vaughan D . Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension. 1998; 32(6):965-71. DOI: 10.1161/01.hyp.32.6.965. View